Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Department of Gastroenterology and Hepatology, Landspitali University Hospital, Reykjavik, Iceland.
Scand J Gastroenterol. 2022 Feb;57(2):239-245. doi: 10.1080/00365521.2021.1998600. Epub 2021 Nov 8.
BACKGROUND/AIMS: Causes of gastrointestinal bleeding (GIB) in patients on oral anticoagulants (OACs) are not well established. The aims of the study were to compare the causes of GIB in patients on OACs and those not on OAC therapy.
A nationwide study of all GIB events in patients on OACs in Iceland from 2014-2019 was conducted. Bleeding events were obtained through ICD-10 codes and review of endoscopy databases, confirmed by review of medical records. For comparison, patients not on OACs from previous Icelandic population-based studies were used.
Among 752 GIB events in 12,005 patients on OACs, 273 (1.9%) had verified upper and 391 (2.7%) had verified lower GIB. For lower GIB, multivariate analysis showed that OAC users were more likely to have colonic polyps (OR 6.6, 95% CI: 2.4 - 17.8, < .001) or colorectal cancer (OR 3.7, 95% CI: 2.0 - 7.0, < .001) but less likely to have ischemic colitis (OR 0.11, 95% CI: 0.04 - 0.26, < .001). For upper GIB, bleeding from mucosal erosions (OR 4.0 95% CI: 2.5 - 7.9, < .001) and angiodysplasia (OR 3.6, 95%CI: 1.5 - 8.6, = .003) were more common in OAC users.
A high proportion of GIB caused by colonic polyps and colorectal cancer among OAC patients indicates that OACs treatment may facilitate cancer diagnosis. The low proportion of ischemic colitis among those on OACs suggests that OACs provide a protective effect against ischemic colitis. OACs seem to increase the bleeding from angiodysplasia and mucosal erosive disease.
背景/目的:口服抗凝剂 (OAC) 患者胃肠道出血 (GIB) 的病因尚不清楚。本研究旨在比较 OAC 治疗患者与未接受 OAC 治疗患者的 GIB 病因。
对 2014-2019 年冰岛所有接受 OAC 治疗的 GIB 患者进行了全国性研究。出血事件通过 ICD-10 编码和内镜数据库进行评估,并通过病历审查进行确认。为了进行比较,使用了来自之前冰岛基于人群的研究中未接受 OAC 治疗的患者。
在 12005 例接受 OAC 治疗的患者中,752 例 GIB 事件中 273 例(1.9%)为明确的上 GIB,391 例(2.7%)为明确的下 GIB。对于下 GIB,多变量分析显示,OAC 使用者更有可能患有结肠息肉(OR 6.6,95%CI:2.4-17.8, < .001)或结直肠癌(OR 3.7,95%CI:2.0-7.0, < .001),但不太可能患有缺血性结肠炎(OR 0.11,95%CI:0.04-0.26, < .001)。对于上 GIB,OAC 使用者黏膜糜烂(OR 4.0,95%CI:2.5-7.9, < .001)和血管发育不良(OR 3.6,95%CI:1.5-8.6, = .003)引起的出血更为常见。
OAC 患者中结肠息肉和结直肠癌引起的 GIB 比例较高表明,OAC 治疗可能有助于癌症诊断。OAC 患者缺血性结肠炎的比例较低表明,OAC 对缺血性结肠炎具有保护作用。OAC 似乎增加了血管发育不良和黏膜糜烂性疾病的出血风险。